Edition:
India

Novo Nordisk A/S (NVO.N)

NVO.N on New York Stock Exchange

53.85USD
4 May 2016
Change (% chg)

$-0.86 (-1.57%)
Prev Close
$54.71
Open
$54.32
Day's High
$54.34
Day's Low
$53.66
Volume
155,071
Avg. Vol
330,042
52-wk High
$60.34
52-wk Low
$46.17

NVO.N

Chart for NVO.N

About

Novo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company's business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1),... (more)

Overall

Beta: 0.78
Market Cap(Mil.): $110,298.00
Shares Outstanding(Mil.): 2,012.56
Dividend: 0.96
Yield (%): 1.75

Financials

  NVO.N Industry Sector
P/E (TTM): 26.19 33.53 41.92
EPS (TTM): 2.09 -- --
ROI: 73.94 13.05 12.53
ROE: 79.90 13.77 13.43
Search Stocks

Diabetes drug test results boost Novo Nordisk

(This April 28 story corrects the fifth paragraph to say that two, not one, other diabetes drugs have positive cardiovascular side-effects)

29 Apr 2016

Novo Nordisk trims 2016 guidance on lower currency exchange rates

April 29 Denmark's Novo Nordisk posted slightly stronger-than-expected first-quarter operating profit but trimmed its 2016 guidance due to lower currency exchange rates.

29 Apr 2016

BRIEF-Novo Nordisk announces positive results from semaglutide trial

* Says semaglutide significantly reduces the risk of major adverse cardiovascular events in Sustain 6 trial

28 Apr 2016

NORDIC STOCKS-Factors to watch on March 29

March 29 - The following stocks may be affected by newspaper reports and other factors on Tuesday:

29 Mar 2016

Novo Nordisk and AstraZeneca seek tonic from key drug trials

LONDON Novo Nordisk and AstraZeneca, two drugmakers whose financial outlooks disappointed investors last month, are both hoping for a boost in the coming weeks from results of two closely watched clinical trials.

01 Mar 2016

Novo Nordisk and AstraZeneca seek tonic from key drug trials

LONDON, March 1 Novo Nordisk and AstraZeneca, two drugmakers whose financial outlooks disappointed investors last month, are both hoping for a boost in the coming weeks from results of two closely watched clinical trials.

01 Mar 2016

CEO of Novo Nordisk's biggest shareholder steps down

COPENHAGEN, Feb 12 Novo A/S, the parent company behind the world's largest insulin maker Novo Nordisk said on Friday Chief Executive Eivind Kolding will step down at the end of the month.

12 Feb 2016

BRIEF-Novo Nordisk says Kolding to not seek re-election for board

* Novo Nordisk A/S: proposed changes in composition of the board of directors of Novo Nordisk

12 Feb 2016

European shares end lower on disappointing U.S data, weak earnings

* Italian lenders lead bank sector lower (Adds details, updates prices)

03 Feb 2016

EXECUTIVE VIEW -Novo optimistic about uptake of Tresiba in the U.S

COPENHAGEN, Feb 3 Novo Nordisk on Wednesday lowered its target for long-term profit growth after a slightly weaker than expected fourth quarter.

03 Feb 2016

Competitors

  Price Chg
Sanofi SA (SASY.PA) €70.13 -1.52
Eli Lilly and Co (LLY.N) $74.98 -1.27

Earnings vs. Estimates

Search Stocks